PTP4A3 and neoplasm: Heterozygous bi-transgenic HA-PRL-3 het/R26-rtTA het mice did not exhibit evident developmental defects, structural abnormalities, lifespan variation, differences in body as well as organ weight, or tumor development after 12 months of dox treatment neither in FA1 (Fig. 1c, d and Fig s1E, F) nor in FB1 (Fig s1G, H, I) compared to the HA-PRL-3 wt/R26-rtTA het control mice.